600 related articles for article (PubMed ID: 32114747)
1. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
Chen C; Zhang XR; Ju ZY; He WF
Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
[TBL] [Abstract][Full Text] [Related]
2. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
Napp LC; Bauersachs J
Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
[No Abstract] [Full Text] [Related]
4. COVID-19: Cytokine storm modulation/blockade with oral polyvalent immunoglobulins (PVIG, KMP01D): A potential and safe therapeutic agent (
Sly LM; Braun P; Woodcock BG
Int J Clin Pharmacol Ther; 2020 Dec; 58(12):678-686. PubMed ID: 33141018
[TBL] [Abstract][Full Text] [Related]
5. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
Xi Y
Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
[No Abstract] [Full Text] [Related]
6. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
Copaescu A; Smibert O; Gibson A; Phillips EJ; Trubiano JA
J Allergy Clin Immunol; 2020 Sep; 146(3):518-534.e1. PubMed ID: 32896310
[TBL] [Abstract][Full Text] [Related]
7. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
Wang J; Jiang M; Chen X; Montaner LJ
J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
[TBL] [Abstract][Full Text] [Related]
8. The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.
Mansourabadi AH; Sadeghalvad M; Mohammadi-Motlagh HR; Rezaei N
Life Sci; 2020 Oct; 258():118185. PubMed ID: 32750438
[TBL] [Abstract][Full Text] [Related]
9. Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification.
Wang Q; Hu Z
Int J Infect Dis; 2020 Jul; 96():618-620. PubMed ID: 32470601
[TBL] [Abstract][Full Text] [Related]
10. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
Henderson LA; Canna SW; Schulert GS; Volpi S; Lee PY; Kernan KF; Caricchio R; Mahmud S; Hazen MM; Halyabar O; Hoyt KJ; Han J; Grom AA; Gattorno M; Ravelli A; De Benedetti F; Behrens EM; Cron RQ; Nigrovic PA
Arthritis Rheumatol; 2020 Jul; 72(7):1059-1063. PubMed ID: 32293098
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Information on the COVID-19 Pandemic continued.
Rock G
Transfus Apher Sci; 2020 Aug; 59(4):102854. PubMed ID: 32660893
[No Abstract] [Full Text] [Related]
12. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
Ye Q; Wang B; Mao J
J Infect; 2020 Jun; 80(6):607-613. PubMed ID: 32283152
[TBL] [Abstract][Full Text] [Related]
13. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.
Rodríguez Y; Novelli L; Rojas M; De Santis M; Acosta-Ampudia Y; Monsalve DM; Ramírez-Santana C; Costanzo A; Ridgway WM; Ansari AA; Gershwin ME; Selmi C; Anaya JM
J Autoimmun; 2020 Nov; 114():102506. PubMed ID: 32563547
[TBL] [Abstract][Full Text] [Related]
14. Convalescent plasma in Covid-19: Possible mechanisms of action.
Rojas M; Rodríguez Y; Monsalve DM; Acosta-Ampudia Y; Camacho B; Gallo JE; Rojas-Villarraga A; Ramírez-Santana C; Díaz-Coronado JC; Manrique R; Mantilla RD; Shoenfeld Y; Anaya JM
Autoimmun Rev; 2020 Jul; 19(7):102554. PubMed ID: 32380316
[TBL] [Abstract][Full Text] [Related]
15. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
16. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
Garraud O
Transfus Apher Sci; 2020 Aug; 59(4):102858. PubMed ID: 32631501
[No Abstract] [Full Text] [Related]
17. Immunotherapeutic approaches to curtail COVID-19.
Owji H; Negahdaripour M; Hajighahramani N
Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
[TBL] [Abstract][Full Text] [Related]
18. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19.
Lin JH; Chen YC; Lu CL; Hsu YN; Wang WJ
J Formos Med Assoc; 2020 Jun; 119(6):1116-1118. PubMed ID: 32359878
[No Abstract] [Full Text] [Related]
19. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
[TBL] [Abstract][Full Text] [Related]
20. Convalescent Plasma: Promise for COVID-19 Pandemic.
Sheikh S; Baig MA
J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
[No Abstract] [Full Text] [Related]
[Next] [New Search]
